{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F45f7d7d6-5b8d-4c0b-98b1-8c5e4aaf456c","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combinations in the Management of Prostate Cancer \u2014 A Clinical Investigator Think Tank\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/45f7d7d6-5b8d-4c0b-98b1-8c5e4aaf456c\"></iframe>","title":"Ready for Prime Time? Determining the Current and Future Role of PARP Inhibitor-Based Combinations in the Management of Prostate Cancer \u2014 A Clinical Investigator Think Tank","description":"\n        <p>Drs Neeraj Agarwal, Emmanuel Antonarakis, Karim Fizazi and Susan Slovin discuss the current and future role of PARP inhibitors in the management of prostate cancer.  </p>\n\n<p>CME information and select publications <a href=\"https://www.researchtopractice.com/PARPProstateThinkTank2023\" rel=\"nofollow\">here</a>.</p>\n      ","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/bf5d94bd-3c9e-4215-afb7-22a1ef6955c6/cover.jpg"}